Oct 23 2020


1:30 pm - 5:30 pm

Theralymph Work Progress Meeting

Due to the restrictive and preventive measures put into place by the European countries, we met on October 23 2020 by videoconference.

 We were honored to introduce our consortium: Dr Kari Alitalo (Finland), Dr Tatiana Petrova (Switzerland), Dr Miikka Vikkula (Belgium), Dr Agnès Noël (Belgium), Dr Lenka Romeislova (Czeck Republic), Dr Gilles Pagès (France), Dr Taija Makinen (Sweden), Flash Therapeutics (France), the Clinical Investigation Center of Toulouse (France) and Inserm Tranfert.

Introduction : Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid/lymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery and lymph node removal (secondary lymphedema). It causes a significant morbidity and is a common disabling disease affecting more than 120 million people worldwide, however there is no curative treatment for lymphedema. Therefore, our main objective will be to establish a multiple gene therapy for lymphedema. We will focus on women who developed secondary lymphedema after breast cancer. This meeting will consist in presenting the work teams as well as the distribution of each work packages in Theralymph project.

Hourly Schedule

Theralymph Work Progress Meeting

13:00 -
Barbara Garmy-Susini
13:30 - 13:40
Short presentation of the amended Theralymph Workprogramme (Gantt, deliverables and milestones)
Christiane Dascher-Nadel (IT, Marseille France)
13:45 - 14:05
Pathophysiology of lymphedema: risk factor associated with lymphedema
Gilles Pagès (CNRS, Nice France)
14:05 - 14:25
Architecture of the collecting vessels in the adipose tissue
Taija Makinen (UU, Uppsala Sweden)
14:25 - 14:45
Gene expression analysis
Miikka Vikkula (DDUV, Brussels Belgium)
14:45 - 15:05
Effect of lipid mediators on the lymphatic endothelium and trafficking of immune cells; knock-down and overexpression of therapeutic targets
Tatiana Petrova (UNIL, Lausanne Switzerland)
15:05 - 15:25
Adipose tissue function in lymphedema; Effect of FFA on lymphatic function
Lenka Romeislova – (CUNI, Prague Czech Republic)
15:25 - 15:35
15:35 - 15:55
Knock-down and overexpression of therapeutic targets
Agnès Noël – ULIEGE, Liège Belgium)
15:55 - 16:15
Gene expression analysis
Kari Alitalo (UnivHel, Helsinki Finland)
16:15 - 16:35
Production of lentivectors and LentiFlash
Régis Gayon (FTX, Toulouse France)
16:35 - 16:55
Lentivectors & therapeutic targets validation
Barbara Garmy-Susini (Inserm, Toulouse France)
16:55 - 17:15
Preparation of the clinical dossier
Alessandra Bura-Rivière (CHUT, Toulouse France)
17:15 - 17:30
Conclusions & general discussion
17:30 -
End of the meeting